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1. Introduction 
Breast cancer is the leading cause of cancer deaths among women in the United States and 
Europe [Jemal et al., 2011]. Most of these women die from their metastases, also known as 
the spread of primary breast cancer cells, to distant organs such as lung, brain and bone 
[Mehrotra et al., 2004]. Metastatic development comprises a complex series of linked, 
sequential steps. These steps include disconnection of intercellular adhesions and separation 
of single cells within a primary tumour, interaction with the surrounding extracellular 
matrix, local migration and invasion, followed by intravasation, transit through blood 
vessels and extravasation at distant organs, where they establish secondary tumours or 
metastases. In other words, the most lethal aspects of breast cancer are the processes of 
tumour cell migration and invasion, both prerequisites for the formation of metastases 
[Yilmaz & Christofori, 2010]. At present, however, the mechanisms responsible for the 
acquisition of invasive and metastatic potential of tumour cells are poorly understood. Thus, 
a better understanding of the biology and molecular interactions that regulate and 
coordinate the steps of tumour cell migration and invasion, is required to effectively treat 
metastatic breast cancer and control the devastating nature of breast cancer. It is widely 
accepted that cancer cells, capable of initiating metastases acquire specific features and exert 
activities that are not shared with the primary tumour cells [Liotta & Kohn, 2001]. Over the 
past years, a number of particular complex invasion-associated cellular activities have been 
recognized and characterized, including variations in expression levels of cell-cell and cell-
matrix adhesion molecules and proteases that degrade the surrounding extracellular matrix, 
along with changes in expression or activity levels of a variety of cellular proteins in 
multiple branched signalling pathways [Mareel & Leroy, 2003]. Additionally, previous 
studies have highlighted the importance of aberrant glycosylation as a crucial event in the 
induction of invasion and metastasis [Hakomori, 2002], including altered glycosylation of 
cell-surface glycoproteins [Kim & Varki, 1997] and GSLs (glycosphingolipids) [Hakomori, 
1998]. GSLs are common components of cell membranes. In malignant cells, they have been 
identified as tumour-associated antigens as defined by specific monoclonal antibodies 
[Hakomori, 1996]. Essentially all GSLs, in tumour and normal cells, can cluster and assemble 
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with specific membrane proteins and signal transducers. Of importance is that clustering of 
particular GSLs may affect cellular activities associated with tumour cell migration and 
invasion, since they are recognized to mediate cell-cell and cell-matrix adhesion and initiate 
signal transduction, induced by stimulation of GSLs [Hakomori et al., 1998]. Roles for GSLs 
in invasion were demonstrated recently for GM3 (monosialoganglioside 3) in mouse 
melanoma B16 cells [Iwabuchi et al., 1998; Iwabuchi et al., 1998] and in human bladder 
KK47 cells [Mitsuzuka et al., 2005], for GM1 in mouse Lewis lung cancer cells [Zhang et al., 
2006], for DSGG (diasyl-GalNAcLc4) in renal cell carcinoma [Satoh et al., 2000; Ito et al., 
2001] and for GD3 (disialoganglioside 3) in melanoma cells [Hamamura et al., 2005]. The 
glycosphingolipid, MSGb5 (monosialyl-Gb5), also known as SSEA-4 (stage-specific 
embryonic antigen-4) [Kannagi et al., 1983], is found maximally expressed in human renal 
cell carcinomas and correlates with metastases [Saito et al., 1991; Saito et al., 1997]. The 
molecular mechanisms regulating synthesis of MSGb5 have been studied previously [Saito 
et al., 2003]; however, no clear functional role of MSGb5 in the invasive and metastatic 
behaviour of tumour cells has been demonstrated. In this chapter, we present data on a 
functional role of the glycosphingolipid MSGb5 in the human mammary carcinoma variant 
cell line MCF-7/AZ, showing increased invasiveness and motility in response to stimulation 
of MSGb5 by its monoclonal antibody RM1 or through induced clustering of MSGb5 by ET-
18-OMe. ET-18-OMe is a synthetic ether lipid analogue shown to induce loss of cell-cell 
adhesion and to stimulate invasion of MCF-7/AZ breast cancer cells [Steelant et al., 2001] 
and was used as a molecular probe in the presented study. 
2. TLC patterns of GSLs from cell extracts of MCF-7AZ and MCF-7/6 cells 
The major GSLs identified in the two human breast cancer cell lines, MCF-7/AZ and MCF-
7/6, were characterized as: globo-series Gb3, Gb4, MsGb5 and ganglio-series structure GM2, 
by TLC developed in a solvent system of chloroform/methanol/aqueous CaCl2 and 
visualized with orcinol staining (Figure 1) [Saito et al., 1971]. Lacto-series structures were 
presumably below the detection limit. 
 
 
Fig. 1. TLC pattern of GSLs from whole cell extracts of MCF-7/AZ and MCF-7/6 cells with or 
without ET-18-OMe. GSLs were extracted from cells of the same protein weight, spotted onto 
TLC plates, developed in a solvent system of chloroform/methanol/0.2% aqueous CaCl2, 
visualized by spraying with 0.5% orcinol in 2M sulfuric acid. CDH (lactosylceramide), Gb3, 
Gb4, MSGb5, GM3, GM1, GD3 and GD1b were used as reference markers.  
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All identified GSLs were present in the insoluble low–density fractions, as prepared after 
elimination of sucrose by dialysis and detected by TLC immunostaining with specific 
monoclonal antibodies (mouse IgM 1A4 to Gb3, mouse IgM 9G7 to Gb4, mouse IgM SSEA-3 
to Gb5, mouse IgM RM1 to MSGb5, mouse IgM MBr1 to globo-H (α1→2 fucosyl-Gb5), 
mouse IgM MK1-8 to GM2, mouse IgG3 DH2 to GM3 and mouse IgM 5F3 to disialyl-Gb5) 
[Kannagi & Hakomori, 2001; Ito et al., 2001] (Figure 2). The cell variants in this study lack 
the abundant presence of GM3 and GM1 as was reported by Nohara et al. (1998) in MCF-7 
cells, but show a comparable expression pattern for Gb3 and other globo-series structures 
similar to Gb5 and globo-H. Furthermore, we found that treatment with the ether lipid ET-
18-OMe did not alter the expression levels of GSLs present in these cell lines. 
 
 
Fig. 2. TLC pattern of GSLs in low-density fractions of MCF-7/AZ and MCF-7/6 cells with 
or without ET-18-OMe. GSL fractions were prepared after elimination of sucrose by dialysis 
using C18 columns. Immunostaining of various GLS structures present in the low-density 
fractions were detected by using nine antibodies directed against the respective structures. 
3. RM1 and ET-18-OMe stimulate motility and invasion through clustering of 
MsGb5 in MCF-7/AZ cells 
The two human breast cancer cell variants, MCF-7/AZ and MCF-7/6, are non-invasive into a 
collagen type I gel-layer as determined by a method using specific assembly [Bracke et al., 
1999] and the motility of the two variants as revealed by wound migration assay is basically 
the same. When MCF-7/AZ cells were treated with monoclonal anti-MSGb5 antibody RM1 or 
with ET-18-OMe, their invasiveness into collagen I layer was greatly enhanced, while no such 
effect could be observed on MCF-7/6 cells. Control IgM antibodies from normal mouse serum 
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and antibodies to other GSLs (anti-globo-H MBr-1, anti-Gb3 1A4, anti-Gb5 SSEA-3, anti-GM2 
MK1-8) [Steelant et al., 2002], did not increase invasiveness of either cell variant (Figure 3).  
 
 
Fig. 3. Invasiveness of MCF-7/AZ cells and MCF-7/6 cells. Effect of mouse IgM or 
antibodies against Globo-H (MBr-1), Gb3 (1A4), Gb5 (SSEA-3), GM2 (MK1-8), MSGb5 (RM1) 
and ET-18-OMe on invasion into collagen type I of MCF-7/AZ cells (open columns) and 
MCF-7/6 cells (black columns). The invasion index expresses the percentage of cells 
invading into collagen type I over the total number of cells after 24 h. Results are means + 
S.D., * indicate statistical difference from control conditions, untreated MCF-7/AZ and 
MCF-7/6 cells, p< 0.05. 
The motility of MCF-7/AZ cells was also enhanced upon treatment with anti-MSGb5 
monoclonal antibody RM1, and again similar treatment did not influence the migratory 
capacity of the other variant cell line, MCF-7/6 (Figure 4).  
 
 
Fig. 4. Migration of MCF-7/AZ and MCF-7/6 cells. Effect of MSGb5 antibody RM1 and ET-
18-OMe on MCF-7/AZ and MCF-7/6 cells in wound migration assay. Confluent cells were 
wounded, measured and allowed to grow in the presence of RM1 and ET-18-OMe. Scale bar 
= 250 µm. After 24 h, the distances over which the cells migrated were measured and results 
are expressed as migratory velocity (µm/h). *, indicate statistical difference from untreated 
MCF-7/AZ and MCF-7/6 cells (p<0.05). 
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Although both cell lines displayed no differences in their GSL composition upon treatment 
with ET-18-OMe, the possibility arose that changes in organization and clustering of GSLs 
could be responsible for the observed biological activity and this presumably through 
assembly with and activation of associated signal transducers. Such an activation model was 
reported for disialylgalactosylgloboside, DSGG, in the renal cell carcinoma cell line TOS-1 
[Satoh et al., 2000] and for GM3 in B16 melanoma cells [Iwabuchi et al., 1998; Iwabuchi et al., 
1998]. Alterations in the organization pattern of MSGb5 were observed by 
immunofluoresescence and confocal microscopy (Figure 5). MSGb5 was detected in both 
variant cell lines MCF-7/AZ and MCF-7/6, which was consistent with the TLC data. 
Fluorescence examination of MCF-7/AZ cells treated with ET-18-OMe revealed clustering of 
MSGb5 at the membrane within minutes. Clustering of MSGb5 in MCF-7/6 cells was not 
observed (data not shown), nor clustering of other GSLs, for example Gb3 and Gb5 in MCF-
7/AZ cells after ET-18-OMe treatment. 
 
 
Fig. 5. Clustering of MSGb5 in MCF-7/AZ cells. The organizational pattern of MSGb5 by 
fluorescence(a) and confocal microscopy(b). Cells in suspension (a) or grown on glass 
coverslips (b-d), and analysed using antibodies against MSGb5, Gb3 and Gb5 and detected 
with FITC-labeled anti-mouse antibody. (a) and (b) show the homogenous organization of 
MSGb5, in untreated MCF-7/AZ cells; arrows indicate clustering of MSGb5 on the 
membrane of MCF-7/AZ cells after 10 and 60 min ET-18-OMe treatment. Organizational 
pattern of Gb3 (c) and Gb5 (d) by confocal microscopy, by using antibodies 1A4 against Gb3 
and SSEA-3 against Gb5, followed by FITC-labeled mouse antibodies. Scale bar = 10 µm. 
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4. Src, the FAK-src signalling complex and the activation of the downstream 
pathway mediating invasion and motility in MCF-7/AZ cells 
Several studies provide evidence that the non-receptor tyrosine kinase, src, is implicated in 
cancer progression of several cancer types. Changes in its expression and tyrosine 
phosphorylation correlate with the acquisition of an invasive cell phenotype [Guarino, 
2010]. The motility and invasion promoting effects of RM1 and ET-18-OMe on MCF-7/AZ 
cells in our studies suggested that RM1 and ET-18-OMe initiate signalling pathways in 
MCF-7/AZ cells but not in MCF-7/6 cells. The possible involvement of src kinase in the 
signalling pathway leading to enhanced migration and invasion could be demonstrated by 
pretreating MCF-7/AZ cells with PP1, a pharmacological inhibitor of src kinase activity in 
the collagen I and wound migration assays (Figure 6).  
 
 
 
Fig. 6. Invasion and migration of MCF-7/AZ and MCF-7/6 cells. Effect of pharmacological 
inhibitor PP1 on RM1 or ET-18-OMe-mediated enhanced invasiveness (left panel) and 
migration of MCF-7/AZ cells (Right panel). Left: Invasion into collagen type I of MCF-7/AZ 
(open columns) and MCF-7/6 cells (black columns). The invasion index expresses the 
percentage of cells invading into collagen type I over the total number of cells. Right: 
Wound migration assay of MCF-7/AZ and MCF-7/6 cells. Scale bar = 250 µm. After 24 h, 
the distances over which the cells migrated were measured and results are expressed as 
migratory velocity (µm/h). *, indicate statistical difference from untreated MCF-7/AZ and 
MCF-7/6 cells (p<0.05). 
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Accordingly, western blotting results revealed that src kinase activity in MCF-7/AZ cells 
was greatly increased within minutes of RM1 or ET-18-OMe treatment, and abolished by 
pretreatment with PP1, while there was no such activation of src by both treatments in 
MCF-7/6 cells. In addition, expression levels of src were left unaltered (Figure 7).  
 
 
Fig. 7. Expression levels of phosphorylated src (Tyr416) upon RM1, RM1 + PP1, ET-18-OMe 
and ET-18-OMe + PP1 treatment in MCF-7/AZ and MCF-7/6 cells. Cells of 70% confluency 
were treated for indicated times, and lysed. Cell lysates, containing 30 µg of proteins, were 
analysed by SDS-PAGE (7.5% gels) and immunoblotted with antibody against src (Tyr416). 
The membrane was stripped at 50°C for 30 min in stripping buffer (100 mM 2-mercapto-
ethanol, 2% (w/v) SDS, 62.5 mM Tris-HCl (pH 6.8)) and reblotted with anti-src antibody, for 
src total expression levels and equal loading. 
These results clearly demonstrated a prominent role for src in motility and invasion 
induced by RM1 and ET-18-OMe. A possible mechanism by which src further promotes 
invasive behavior is through formation of a transient complex with focal adhesion kinase 
(FAK) [Hauck et al., 2002; Hsia et al., 2003]. FAK is another non-receptor tyrosine kinase 
recognized in cancer progression since it is found upregulated in malignant human 
tumour samples [Chatzizacharias et al., 2008]. Correspondingly, in our western blotting 
studies, RM1 and ET-18-OMe treatment increased the activity of FAK at tyrosine residue 
397 (FAK Tyr397), the major autophosphorylation site [Parsons, 2003], in MCF-7/AZ cells 
and this also within minutes of treatment, while chemical levels of FAK remained 
unchanged (Figure 8). Similar treatment of MCF-7/6 cells did not change the activation of 
FAK Tyr397. 
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Fig. 8. Expression levels of phosphorylated FAK (Tyr397) upon RM1 and ET-18- OMe 
treatment in MCF-7/AZ and MCF-7/6 cells. Cells of 70% confluency were treated for 
indicated times, and lysed. Cell lysates, containing 30 µg of proteins, were analysed by SDS-
PAGE (7.5% gels) and immunoblotted with antibody against FAK (Tyr397). The membrane 
was stripped and reblotted with anti-FAK, for FAK total expression levels and equal 
loading. 
FAK plays an important role in relaying signals to intracellular targets, such as src, 
generated by cellular adhesion molecules and other cell surface molecules when they 
interact with the surrounding extracellular matrix [Parsons, 2003; Mitra et al., 2005]. The 
activation of FAK results in increased phosphorylation at Tyr397, the major 
autophosphorylation site, and subsequently in the recruitment and binding of src through 
its SH2 domain and further stabilization of the src-FAK interaction by src’s SH3 domain 
[Thomas et al., 1998]. The formation of this transient bipartite kinase complex disrupts an 
inhibitory intramolecular interaction, resulting in increased activity of src [Schaller et al., 
1994; Xing et al., 1994]. The specific organization plays a crucial role in src-dependent and 
mediated phosphorylation of other tyrosine residues on FAK within the kinase domain 
activation loop (Tyr576 and Tyr577) and at the C-terminal domain residues, Tyr861 and 
Tyr925 [Calalb et al., 1995; Calalb et al., 1996; Schlaepfer et al., 1996]. Interesting is that the 
activated FAK (Tyr397)-src signalling complex allows the activation of multiple different 
downstream pathways depending on which specific tyrosine residue on FAK is activated 
[Brunton et al., 2005]. As shown in scheme 1, the activated FAK-src complex can result in the 
activation of the mitogen-activated protein kinase (MAPK)-cascade through FAK Tyr925 
[Schlaepfer et al. 1998], p130Cas via FAK Tyr861 [Lim et al., 2004] or paxillin by FAK Tyr576 
[Calalb et al., 1995]. These three signalling pathways downstream of the FAK-src signalling 
complex, all lead to increased release of matrix metalloproteinase-2 (MMP-2) and MMP-9, 
the major proteinases responsible for the degradation of collagen type I [Kurata et al., 2000; 
Liu et al., 2000; Hsia et al., 2003; Brabek et al., 2004; Brabek et al., 2005; Bjorklund & 
Koivunen, 2005].  
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Scheme 1. Possible pathways downstream of the transient FAK-src complex leading to 
increased expression of MMPs, facilitating invasion into collagen type I layer. 
Our results support that ET-18-OMe treatment results in the formation of a temporary FAK-
src complex through FAK (Tyr397) activation and the subsequent src-dependent 
phosphorylation of FAK on Tyr925, since pretreatment of MCF-7/AZ cells with PP1, 
blocked the activation of src (Figure 7) and FAK Tyr925, while the activation of FAK at 
Tyr397 was only partially reduced (Figure 9). These results also point out that ET-18-OMe-
mediated activation and autophosphorylation of FAK at Tyr397 is upstream and required 
for the activation of src and that src activity is responsible for the activation of the additional 
tyrosine residue 925 of FAK but not of FAK Tyr576 and 861 (Figure 9). Furthermore, we 
provide evidence linking FAK Tyr925 phosphorylation to the activation of the MAPK-
pathway, since treatment of MCF-7/AZ cells with ET-18-OMe resulted in the downstream 
activation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and PP1 blocked the 
enhanced activation. In addition, we demonstrated that p130Cas and paxillin, which are 
known substrates of src associated with phosphorylation of FAK on Tyr861 and 576 
respectively [Lim et al., 2004; Calalb et al., 1995], are not involved in the ET-18-OMe-induced 
effect and confirmed the lack of phosphorylation at FAK Tyr861 and 576 (Figure 10). 
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Fig. 9. Expression levels of FAK (Tyr397, Tyr925) upon ET-18-OMe and ET-18-OMe + PP1 
treatment in MCF-7/AZ and MCF-7/6 cells. Cells of 70% confluency were treated for 
indicated times, and lysed. Cell lysates, containing 30 µg of proteins, were analysed by SDS-
PAGE (7.5% gels) and immunoblotted with antibodies against FAK (Tyr397, Tyr576, Tyr861 
and Tyr925). The membranes were stripped and reblotted with anti-FAK, for FAK total 
expression levels and equal loading. 
 
 
Fig. 10. Expression levels of ERK (Thr202/Tyr204) upon ET-18-OMe and ET-18-OMe + PP1 
treatment in MCF-7/AZ and MCF-7/6 cells. Cells of 70% confluency were treated for 
indicated times, and lysed. Cell lysates, containing 30 µg of proteins, were analysed by SDS-
PAGE (7.5% gels) and immunoblotted with antibodies against ERK (Thr202/Tyr204), 
p130Cas (Tyr410) and paxillin (Ser178). The membranes were stripped and reblotted with 
anti-ERK, anti-p130Cas and paxillin for total ERK, p130Cas and paxillin expression levels 
and equal loading. 
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5. MSGb5 activates the FAK-src signalling complex 
Tumour cell invasion includes alterations of expression levels of integrin receptors. Integrin 
receptors are important upstream regulators of intracellular and downstream signalling 
events associated with cancer cell invasion. This family of heterodimeric α/β subunit 
receptors, expressed on every cell type, is capable of interacting with specific ligands in the 
surrounding extracellular matrix. Binding to these components results in clustering of 
integrin receptors in the plasmamembrane and recruitment and association of signalling 
proteins with integrin cytoplasmic domains to initiate downstream signalling events 
[Schwartz, 2001]. Since src and FAK are recognized as two critical mediators of integrin 
signalling, we addressed the question whether particular integrins were implicated in ET-
18-OMe-induced activation of FAK and src and invasiveness of MCF-7/AZ cells. The 
integrin receptors α1β1 and α2β1 are the major receptors binding to collagen type I in the 
extracellular matrix [Gullberg et al., 1992]. Given that RM1 and ET-18-OMe induce 
invasiveness of MCF-7/AZ cells in collagen type I layer, we examined the expression levels 
of integrin subunits α1, β1 and α2 upon treatment with ET-18-OMe by Western blotting. 
Expression of the α1 and β1 subunits were found decreased over time in MCF-7/AZ cells, 
and no changes of either integrin subunit was observed in the variant cell line (Figure 11), 
whereas the integrin α2 subunit was not detectable in both cell lines (data not shown).  
 
 
Fig. 11. Expression of integrin subunits α1 and β1 in MCF-7/AZ and MCF-7/6 cells upon 
ET-18-OMe treatment. Cells of 70% confluency were treated for indicated times, and lysed. 
Cell lysates, containing 30 µg of proteins, were analysed by SDS-PAGE (7.5% gels) and 
immunoblotted with antibodies against the integrin α1 and β1 subunit. 
Since activation of integrin-dependent signalling occurs via clustering of integrin receptors 
and association with FAK signalling elements to the cytoplasmic tails of the receptor 
[Miyamoto et al., 1995], organizational patterns of the α1 and β1 subunits and co-clustering 
with signalling molecules FAK and src, upon ET-18-OMe treatment were examined by 
fluorescence microscopy and co-immunoprecipitation experiments. The microscopy data 
revealed that ET-18-OMe did not change the organization of the respective integrin subunits 
and the fact that signalling molecules FAK and src could not be detected in the 
immunoprecipitates of either integrin subunits confirmed that integrin receptors α1β1 and 
α2β1 were not of crucial importance in the activation of downstream signalling events in 
MCF-7/AZ cells mediated by ET-18-OMe or RM1 (data not shown). This was in sharp 
contrast with data reported by other investigators [Schaller et al., 1995]. However, the 
recognition that glycosphingolipids may influence cellular phenotype by clustering and 
assembly with signal transducing molecules, let us to explore the possible involvement of 
the glycosphingolipid MSGb5 in initiating the signalling events in MCF-7/AZ cells upon 
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RM1 or ET-18-OMe treatment. This idea was supported by two of our observations namely 
that RM1 and ET-18-OMe treatment resulted in clustering of MSGb5 in MCF-7/AZ cells and 
that similar treatment profoundly affected the cellular activities associated with the 
migratory and invasive capacity of MCF-7/AZ cells. A close connection between MSGb5 
and signalling molecules was shown by co-immunoprecipitation experiments, in which 
aliquots of cell lysates were immunoprecipitated by incubation with anti-MSGb5 antibody 
and captured with protein G-Sepharose beads. The signalling molecules, FAK and src as 
well as their activated forms, src (Tyr416) and FAK (Tyr397), were detected in MSGb5 
immunoprecipitates prepared from MCF-7/AZ cells treated with ET-18-OMe for indicated 
time points, and the obtained results were in line with the earlier performed kinase 
experiments. In MCF-7/6 cells, FAK and src were found associated with MSGb5, and as 
expected no kinase activity was observed upon ET-18-OMe treatment (Figure 12). The 
involvement of other glycosphingolipids could be excluded since no clustering and no 
association between FAK and src with Gb3, Gb5 or GM2 (data not shown) could be found in 
MCF-7/AZ cells. Equal levels of MSGb5 were detected in the immunoprecipitates of both 
cell lines. 
 
 
Fig. 12. MSGb5 associates with src (Tyr416) and FAK (Tyr397) in MCF-7/AZ cells after ET-
18-OMe treatment. MSGb5 was immunoprecipitated from whole cell lysates with mouse 
IgG3 anti-MSGb5 antibody. Aliquots of immunoprecipitates were electrophoresed, 
transferred and immunoblotted, with anti-src (Tyr416), anti-src, anti-FAK (Tyr397) and anti-
FAK. MSGb5 content in the different immunoprecipitates was determined by TLC.  
6. Concept of “Glycosynapse” 
Glycosphingolipids are highly expressed during defined stages of development and after 
oncogenic transformation and are referred to as stage-specific embryonic antigen and 
tumour-associated antigens respectively [Hakomori, 1998]. Most studies, however, use the 
presence of GSLs as markers of low-density membrane fractions and are neither focused on 
their structural variety nor their possible functional roles. In this chapter, we present data 
supporting a functional role for MSGb5 in migration and invasion of MCF-7/AZ cells upon 
stimulation with RM1 or treatment with ET-18-OMe, resulting in MSGb5 clustering and 
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activation of associated signalling molecules. These observations can be placed in the 
concept of the ‘glycosynapse’ [Hakomori, 2002]. This term defines glycosylation-dependent 
adhesion and signalling, mediated via glycosylepitopes of GSLs in microenvironments 
where tumour cells interface with other tumour cells, host cells or the surrounding matrix, 
in analogy to the ‘immune synapse’ which on its turn controls functional adhesion and 
signalling between immunocytes [Ilangumaran et al., 2000]. In addition to glycosylation-
dependent adhesion of GSLs between interfacing glycosynapses, conversion of phenotypes 
is highly controlled by the presence, interactions and organization of other crucial molecules 
in the glycosynapse, such as growth factor receptors, integrin receptors, tetraspanins, 
mucins and gangliosides [Hakomori & Handa, 2002]. Furthermore, this new concept has 
been extended to phenotypic conversion induced through the deletion or addition of a 
single component, resulting in a disorganized glycosynapse framework and initiating 
altered signalling events [Mitsuzuka et al., 2005]. We can relate our observations to the latter 
revised glycosynapse concept and more specifically to the formation of a disorganized 
glycosynapse framework. We conclude that phenotypic conversion from non-invasive to 
invasive MCF-7/AZ breast cancer cells is induced by: (i) an aberrant MSGb5 pattern; (ii) loss 
of integrin receptor subunits ┙1 and ┚1; and (iii) high tetraspanin CD9 expression levels 
[Steelant et al., 2002], all of which are responsible for the formation of disorganized 
glycosynapse framework interfaces, thereby inducing activation of FAK, src and 
downstream ERK, with consequent enhanced secretion and activity of MMP-2 and MMP-9, 
and thus leading to invasion. 
 
 
Scheme 2. Cancer cell invasion revised. In non-invasive MCF-7/AZ cells integrin subunits α1 
and β1 form a stable complex with tetraspanin CD9 and GLSs, associated with non-active 
signalling molecules, FAK and src. In invasive MCF-7/AZ cells clustering of MSGb5 and loss 
of integrin subunits α1 and β1 disorganize the glycosynapse framework, resulting in activation 
of downstream signalling to invasion. EC, extracellular; IC, intracellular; TSP, tetraspanin. 
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7. Conclusion 
In conclusion, our studies are an extension of previous work on the glycosynapse 
[Hakomori, 2002], re-formulating the classic concept of integrin-dependent invasion of 
tumour cells and providing evidence that phenotypic conversion can be explained by 
differences in composition and organization of crucial molecules in the glycosynapse. At 
present, only a few studies have appeared that focus, in particular, on GM3 [Mitsuzuka et 
al., 2005, Toledo et al., 2005]. The present study reveals a novel insight into the composition 
and organization of the glycosynapses in MCF-7/AZ breast cancer cells, which explain 
phenotypic changes. Further studies along this line are necessary to understand the complex 
interplay of distinct molecules in invasion, as well as other basic cellular mechanisms, and 
their implications on disease processes, which will be expected to lead to novel therapeutic 
approaches. 
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